Alpha Centric Advisors LLC Gracell Biotechnologies Inc. Transaction History

Alpha Centric Advisors LLC

  • $118 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 25, 2022
SELL
$5.65 - $14.9 $96,050 - $253,300
-17,000 Closed
0 $0
Q3 2021

Mar 09, 2022
BUY
$9.91 - $14.84 $168,470 - $252,280
17,000 New
17,000 $236,000
Q2 2021

Mar 09, 2022
SELL
$9.75 - $18.42 $185,250 - $349,980
-19,000 Closed
0 $0
Q1 2021

Mar 09, 2022
BUY
$14.7 - $30.57 $279,300 - $580,830
19,000 New
19,000 $293,000

Others Institutions Holding GRCL

# of Institutions
2
Shares Held
75.1K
Call Options Held
0
Put Options Held
0
View Full List

About Gracell Biotechnologies Inc.

GRCL Quotes by TradingView
  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email